Table 2.
Clinical variables by subtypes and bibliographical reference to the article in which they appear.
| Subtype of Clinical Data | Variables | Used by |
|---|---|---|
| Demographic data | Age at diagnosis | [70,71,72,73,74,75,76,77,79,80,81,82,83,84,85,87,89,92,97,98,100,104,107] |
| Gender | [76,80,82,85,87,89,92,97,98,104,107] | |
| Ethnicity | [72,73,80,89,98,107] | |
| General measures of health status | BMI | [73,75,81,82,98] |
| Temperature | [98] | |
| Respiration rate | [98] | |
| Systolic and diastolic blood pressure | [73,98] | |
| Heart rate | [73,98] | |
| Menopausal status | [79,81,89,97] | |
| Lifestyle (e.g., smoking habit) | [85] | |
| Prior malignancies | [107] | |
| Presence/absence of comorbidities (e.g., hypercholesterolemia, hypertension, diabetes mellitus, synchronous malignancies, etc.) | [73,75,81,85,89,98,107] | |
| Number of comorbidities | [98] | |
| Risk factors (e.g., high sensitivity to C reactive protein, etc.) | [76,82,98] | |
| Laboratory test results data |
Blood cells count (e.g., leukocytes, platelets) | [73,98] |
| Haemoglobin level | [73,82] | |
| Serum metabolites/enzymes level (e.g., sugar, urea, creatinine, bicarbonate, albumin, lactate dehydrogenase, etc.) | [73,81,82,98] | |
| Surgery-related data | Surgery time | [75] |
| Median blood lost | [75] | |
| Presence of intraoperative complications | [75] | |
| Type of complications | [75] | |
| Length of hospital stay | [75] | |
| Pathological data | Mode of detection (clinical or screening) | [70] |
| Cancer type (primary site) | [80,85,107] | |
| Cellularity of tumour content | [79] | |
| Degree of abnormality of cancer cells | [79] | |
| Primary tumour laterality | [79] | |
| Primary tumour size | [70,72,74,75,79,83,86,89] | |
| Presence/absence of multifocal tumours | [86] | |
| Surgery status | [73,79] | |
| Type of surgery | [74,84,89] | |
| Resection extent | [87] | |
| Parametrial involvement (in cervical cancer) | [75] | |
| Skin or chest wall invasion (in breast cancer) | [86] | |
| Lymph node status | [75] | |
| Number of positive lymph nodes | [70,72,83,86,89,92,97] | |
| Lymph node involvement ratio | [74,75] | |
| Lymph-vascular space invasion | [72,75] | |
| Deep stromal invasion | [75] | |
| Histologic type and subtype | [72,73,75,76,84,92,97] | |
| Histological grade | [70,75,76,80,81,83,84,85,86,87,89,92,99,105] | |
| T Stage | [82] | |
| N Stage | [82,92] | |
| M Stage | [86,92,105,107] | |
| Stage (e.g., pTNM, NPI, FIGO staging system) | [73,75,76,79,81,84,85,92,97,101,105,107] | |
| Number of brain metastases | [71] | |
| Presence/absence of distant metastasis at diagnosis | [72] | |
| Therapy-related data | Prior treatment | [89,107] |
| Radiotherapy (yes/no) | [73,75,85,89,97,98,107] | |
| Chemotherapy (yes/no) | [70,73,79,89,98,107] | |
| Targeted therapy (yes/no) (e.g., hormonal therapy, anti-HER2 therapy, etc.) | [70,74,79,86,89,98,107] | |
| Response to chemotherapy (complete/partial/none) | [86] | |
| Karnofsky Performance Status (KPS) | [71] |
Abbreviations: BMI, Body Mass Index; pTNM, pathological Tumour-Node-Metastasis staging system for cancers of the American Joint Committee on Cancer (AJCC); NPI, Nottingham Prognostic Index; FIGO, Fédération Internationale de Gynécologie et d’Obstétrique.